213 related articles for article (PubMed ID: 35840818)
1. Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing.
Maddali M; Venkatraman A; Kulkarni UP; Mani S; Raj S; Sigamani E; Korula A; A FN; Lionel SA; Selvarajan S; Manipadam MT; Abraham A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2022 Sep; 101(9):1987-2000. PubMed ID: 35840818
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
3. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
4. Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.
Tharakan S; Mascarenhas J; Tremblay D
Leuk Lymphoma; 2024 Feb; 65(2):158-167. PubMed ID: 38033130
[No Abstract] [Full Text] [Related]
5. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
6. Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.
Tan J; Chow YP; Zainul Abidin N; Chang KM; Selvaratnam V; Tumian NR; Poh YM; Veerakumarasivam A; Laffan MA; Wong CL
BMC Med Genomics; 2022 Jan; 15(1):10. PubMed ID: 35033063
[TBL] [Abstract][Full Text] [Related]
7. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
8. Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort.
Michail O; McCallion P; McGimpsey J; Hindley A; Greenfield G; McAllister R; Feerick J; Arnold C; Cross N; Cuthbert R; McMullin MF; Catherwood MA
J Clin Pathol; 2021 Dec; 74(12):808-811. PubMed ID: 33144355
[TBL] [Abstract][Full Text] [Related]
9. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
[TBL] [Abstract][Full Text] [Related]
11. Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN.
Zhang J; Shen K; Xiao M; Huang J; Wang J; Wang Y; Hong Z
Front Genet; 2023; 14():1198834. PubMed ID: 37396034
[No Abstract] [Full Text] [Related]
12. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].
Tan YX; Xu N; Huang JX; Wu WE; Liu L; Zhou LL; Liu XL; Yin CX; Xu D; Zhou X
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):576-582. PubMed ID: 32810965
[No Abstract] [Full Text] [Related]
14. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.
Chang YC; Lin HC; Chiang YH; Chen CG; Huang L; Wang WT; Cheng CC; Lin J; Chang YF; Chang MC; Hsieh RK; Chen SJ; Lim KH; Kuo YY
Med Oncol; 2017 May; 34(5):83. PubMed ID: 28389907
[TBL] [Abstract][Full Text] [Related]
15. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
[TBL] [Abstract][Full Text] [Related]
16. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
17. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W; Kralovics R
Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
[TBL] [Abstract][Full Text] [Related]
18. Recent insights regarding the molecular basis of myeloproliferative neoplasms.
Jang MA; Choi CW
Korean J Intern Med; 2020 Jan; 35(1):1-11. PubMed ID: 31778606
[TBL] [Abstract][Full Text] [Related]
19. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
20. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]